Whitepaper

Research spotlight: new therapeutic targets focusing on aberrant lipid metabolism in Alzheimer’s disease

aberrant512

As the global population ages and life expectancy increases, neurodegenerative disorders like Alzheimer’s disease (AD) have the potential to overwhelm the healthcare system. One of the major challenges we currently face is sparse drug discovery pipelines and low clinical trial success rates due to the variability of drug efficacy in individuals. This whitepaper explores new therapeutic targets focusing on Aberrant Lipid Metabolism in Alzheimer's Disease.

For research use only. Not for use in diagnostic procedures.

To view the full content please answer a few questions

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Download Resource

Research spotlight: new therapeutic targets focusing on aberrant lipid metabolism in Alzheimer’s disease

Download Whitepaper